Abstract
The neurodegenerative disorder Alzheimers disease (AD) is the most common form of dementia. It is characterized by progressive impairment of cognitive functions and behavior. To distinguish clinically AD from other forms of dementia is an ongoing challenge. In addition, although mild cognitive impairment (MCI) is recognized as a risk factor for dementia, it remains a challenge to predict on an individual level who will convert to become demented. Amyloid β (Aβ) is one of the crucial pathological findings in AD. Recently, amyloid tracers for PET imaging have been developed successfully which may offer the unique possibility for measuring fibrillar Aβ load in the living brain. Therefore, in the near future positron emission tomography (PET) may become an important tool for in vivo amyloid imaging contributing to early (differential) diagnosis as well as evaluation of treatment response in AD. Moreover, Aβ may play a role in prediction the conversion of MCI to AD. In this paper we review the recent development of the molecular imaging technique PET and its different radiopharmaceuticals on the trail for imaging amyloid in AD and the conversion of MCI to AD.
Current Alzheimer Research
Title: Amyloid PET and MRI in Alzheimers Disease and Mild Cognitive Impairment
Volume: 6 Issue: 3
Author(s): E. Dimou, J. Booij, M. Rodrigues, H. Prosch, J. Attems, P. Knoll, B. Zajicek, R. Dudczak, G. Mostbeck, C. Kuntner, O. Langer, T. Bruecke and S. Mirzaei
Affiliation:
Abstract: The neurodegenerative disorder Alzheimers disease (AD) is the most common form of dementia. It is characterized by progressive impairment of cognitive functions and behavior. To distinguish clinically AD from other forms of dementia is an ongoing challenge. In addition, although mild cognitive impairment (MCI) is recognized as a risk factor for dementia, it remains a challenge to predict on an individual level who will convert to become demented. Amyloid β (Aβ) is one of the crucial pathological findings in AD. Recently, amyloid tracers for PET imaging have been developed successfully which may offer the unique possibility for measuring fibrillar Aβ load in the living brain. Therefore, in the near future positron emission tomography (PET) may become an important tool for in vivo amyloid imaging contributing to early (differential) diagnosis as well as evaluation of treatment response in AD. Moreover, Aβ may play a role in prediction the conversion of MCI to AD. In this paper we review the recent development of the molecular imaging technique PET and its different radiopharmaceuticals on the trail for imaging amyloid in AD and the conversion of MCI to AD.
Export Options
About this article
Cite this article as:
Dimou E., Booij J., Rodrigues M., Prosch H., Attems J., Knoll P., Zajicek B., Dudczak R., Mostbeck G., Kuntner C., Langer O., Bruecke T. and Mirzaei S., Amyloid PET and MRI in Alzheimers Disease and Mild Cognitive Impairment, Current Alzheimer Research 2009; 6 (3) . https://dx.doi.org/10.2174/156720509788486563
DOI https://dx.doi.org/10.2174/156720509788486563 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases
Current Aging Science Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus
Current Proteomics AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer’s Disease
Current Neuropharmacology Phosphatidylserine and Curcumin Act Synergistically to Down-Regulate Release of Interleukin-1β from Lipopolysaccharide-Stimulated Cortical Primary Microglial Cells
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Mechanisms of Atherogenesis and Development of Anti-Atherosclerotic Therapy)
Current Pharmaceutical Design Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Resilient Brain Aging: Characterization of Discordance between Alzheimer’s Disease Pathology and Cognition
Current Alzheimer Research Anatomical Correlates of the Neuropsychiatric Symptoms in Alzheimer’s Disease
Current Alzheimer Research Systems Biology Research into Cardiovascular Disease: Contributions of Lipidomics-based Approaches to Biomarker Discovery
Current Drug Discovery Technologies Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design The Therapeutic Potential of Purinergic Receptors in Alzheimer’s Disease and Promising Therapeutic Modulators
Mini-Reviews in Medicinal Chemistry Gender and Cardiovascular Mortality in Northern and Southern European Populations
Current Pharmaceutical Design 14-3-3 Protein in CSF Reflects SIV-Mediated Pre-Synaptic Damage
Current HIV Research